Navigation Links
Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5

ensity Lipoprotein (HDL), often called "good cholesterol." Its drug candidates relate to the various roles of HDL as a transport vehicle, including removing excess cholesterol from the body, delivering molecules to cells and removing unwanted materials from the body. Liponex is listed on the TSX under the ticker "LPX". For
more information on Liponex, visit www.liponex.ca.

Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The
Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's periodic regulatory filings, which can be found in the SEDAR database at www.sedar.com.

-30-
For further information contact:
Investor Relations Media Relations
Joanna Longo Linda Forrest
The Equicom Group Inc. inmedia Public Relations
(416) 815-0700 ext. 233 (613) 234-7227 ext. 234
jlongo@equicomgroup.com lforrest@inmedia.com
'"/>




Page: 1 2 3

Related medicine technology :

1. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Liponex Inc Reports Phase Clinical Trial Data for CRD5
(Date:5/16/2008)... Highlights Include:, -- Results demonstrating th...linically meaningful extension of progression-free...mab to attack both the inside and,outside of the H...ade, -- Data demonstrating activity of TYKERB alo...ple lines of trastuzumab and chemotherapy, LONDON...
(Date:5/16/2008)... MicroRNAs as Potential Biomarkers -- for Lung Ca... in Patients With Cancer of Unknown Primary ...tively Identify Cancer Types With High Sensitivity...sis and Treatment of Cancer Results of microRNA S... Accuracy Exceeding 90% and Specificity of...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 1PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 2CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 1CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 2TOFUTTI Announces 2007 Results 16776 1TOFUTTI Announces 2007 Results 16776 2TOFUTTI Announces 2007 Results 16776 3TOFUTTI Announces 2007 Results 16776 4TOFUTTI Announces 2007 Results 16776 5Testosterone Spray Improves Sexual Satisfaction in Women 16771 1Testosterone Spray Improves Sexual Satisfaction in Women 16771 2
(Date:5/16/2008)... that Primary care medicine is in a precipitous de...merican College of Physicians (ACP), today joined...sumers to issue a call for comprehensive reforms t...nd other primary care physicians. , During a pa...ne in the U.S., Dr. Dale and other panelists spoke...
(Date:5/16/2008)...ervices for Frail Seniors and People With,Disabili...ire/ -- Thousands of,homecare workers across the s...proposed cuts to hours of service, wages and benef...ulnerable workers and the,people they serve deeper...rvices for seniors and people with disabilities fr...
(Date:5/16/2008)...alth Institute with 10,000 Sensual O Condom Packs ...Mansion Fundraiser, LOS ANGELES, May 16 /PRNewswi... B artist J Kwon known best for his hit song "Ever...ng the Urban Health Institute (UHI) with,10,000 Se... The donation is,being made to promote the launch ...
(Date:5/16/2008)... who would benefit most from chemo after surgery, ... News) -- A panel of 15 genes may help determine w... cancer will experience a recurrence and, therefor... shows. , By extension, the same genetic signa...ve forms of the cancer who would be able to forego...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3
...t deadly form of skin cancer , advanced melanoma c...ts with tumor proteins, say researchers according ...ect vaccinating patients with tumor antigens (call...e cells, which are known as killer T-cells. It was...
...iscovery could help prevent complications for preg...lampsia. Preeclampsia typically develops after the...gh blood pressure, // edema, and protein in the u...here a sharp rise in blood pressure causes the mot...
... killer cells are part of the body’s immune system...ome cancers, particularly leukemia. A new study sh...emia // patients may lie in artificially stimulat...member. Researchers say this method could help tr...
...hers say they have found that stem cell therapy is...uring the study injecting stem cells from one pig'...ig's damaged heart muscle restored the heart's fun...hers studied 14 pigs, whose circulatory systems ar...
Other Medicine News:
... Substitutes a natural alternative to autografts. ... but such grafts may introduce the risk of immune ... has developed the Pro Osteon family of bone graft...s a broad range of bone grafting alternatives that...
Schuknecht-Weitlaner retractor, sharp, angled arms.
Sharp Weitlaner Retractor.
Baby Weitlaner retractor, blunt, 4".
Medicine Products: